{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:59:15Z","timestamp":1773323955185,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T00:00:00Z","timestamp":1432166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2015,9]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>To compare the overall survival (OS<\/jats:styled-content>) of patients with advanced lung adenocarcinoma in C<\/jats:styled-content>hina before and after the approved use of gefitinib, and analyze clinical factors that may affect OS<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>Clinical data of 558 patients with advanced lung adenocarcinoma who received chemotherapy from J<\/jats:styled-content>anuary 2002 to D<\/jats:styled-content>ecember 2010 were retrospectively analyzed. According to the matched\u2010pair case\u2010control study design, 255 patients who only received chemotherapy and 255 patients who received gefitinib treatment after its approval were stringently matched by age, gender, and smoking history and enrolled in the study. Clinical factors including age, gender, smoking history, E<\/jats:styled-content>astern C<\/jats:styled-content>ooperative O<\/jats:styled-content>ncology G<\/jats:styled-content>roup (ECOG)<\/jats:styled-content> performance status (PS)<\/jats:styled-content>, tumor stage, organ metastasis, and the number of prior chemotherapies were analyzed to determine their correlations with OS<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>The median survival time (MST<\/jats:styled-content>) of the 510 enrolled patients with advanced lung adenocarcinoma was 22.8 months. The MST<\/jats:styled-content> of the patients who received gefitinib treatment was significantly longer than that of patients who did not receive gefitinib treatment (33.5 vs. 14.1 months, P<\/jats:italic> < 0.001). The OS<\/jats:styled-content> in patients who received gefitinib treatment was significantly longer than in patients who did not receive gefitinib treatment in almost all clinical factor\u2010based subgroups, including age, gender, smoking history, ECOG PS<\/jats:styled-content> 0\u20131, tumor stage, the presence or absence of lung, pleural, bone, brain, adrenal gland and liver metastasis, and the number of prior chemotherapies (all P<\/jats:italic> < 0.001), except in the ECOG PS<\/jats:styled-content> \u22652 subgroup.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Gefitinib treatment significantly improved the survival of patients with advanced lung adenocarcinoma in C<\/jats:styled-content>hina.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.12267","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T04:00:02Z","timestamp":1432267202000},"page":"636-642","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in C<\/scp>hina"],"prefix":"10.1111","volume":"6","author":[{"given":"Yu\u2010Tao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue\u2010Zhi","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun\u2010Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing\u2010Sheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi\u2010Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong\u2010Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao\u2010Hong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang\u2010Ru","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan\u2010Kai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Institute\/Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10050-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941001)74:7 <2101::AID-CNCR2820741718>3.0.CO;2-M"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20006"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2354"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2095"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.04.021"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060001-00004"},{"key":"e_1_2_8_10_1","first-page":"5749","article-title":"ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy","volume":"62","author":"Wakeling AE","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67625-8"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01243894-200610000-00014"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603710"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61758-4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000205386"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.12267","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.12267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:02:53Z","timestamp":1696183373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.12267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/1759-7714.12267"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.12267","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,21]]},"assertion":[{"value":"2015-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}